Drugs / Type A Botulinum toxin
Type A Botulinum toxin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00213577 | Dec 2003 → Sep 2007 | overactive bladder | University Hospital, Rouen | Terminated | Missed primary |
| Comparator or background therapy1 trial | ||||||
| — | NCT02325063 Comparator | Dec 2015 → May 2017 | epicondylitis | Nîmes University Hospital | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2026-01-09 | Huons Biopharma | Regulatory Huons BioPharma Secures NMPA Approval for Type A Botu-linum Toxin in China huonsbiopharma.com ↗
Huons BioPharma Co., Ltd. (CEO: Yeong-Mok Kim) announced on the 9th that its Chinese partner, IMeik Technology, has received marketing authorization from the National Medical Products Administration (NMPA) of China for Hutox (domestic brand name: LIZTOX). |
| 2025-07-31 | Evolus, Inc. | Results Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins evolus.com ↗
Jeuveau ® and Dysport ® demonstrated significantly faster visible effects at Day 3 compared to Botox ® and Xeomin ® . |
| 2025-06-24 | Teijin America, Inc. | Regulatory Teijin Pharma Receives Approval for Additional Indication for XEOMIN® in Japan[Teijin Pharma] teijin.com ↗
XEOMIN® has become the first-ever drug approved for this indication in Japan. |
| 2025-06-24 | Merz Therapeutics GmbH | Regulatory Teijin Receives Approval for Additional Indication for XEOMIN® in Japan merztherapeutics.com ↗
Teijin Pharma Limited , the core company of Teijin Group ’s healthcare business, and Merz Therapeutics GmbH , a leader in the field of neurotoxins, jointly announced today that Teijin Pharma has received approval from Japan’s Ministry of Health, Labor and Welfare (MHLW) for an additional indication for XEOMIN ® (incobotulinumtoxinA) for the treatment of chronic sialorrhea. |
| 2024-12-20 | Merz Aesthetics Inc. | Results MERZ AESTHETICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 STUDY OF XEOMIN® (incobotulinumtoxinA) FOR TREATMENT OF PLATYSMA PROMINENCE merzaesthetics.com ↗
The study met its primary endpoint. |
| 2023-06-12 | Merz Aesthetics Inc. | Results MERZ AESTHETICS ANNOUNCES POSITIVE PHASE 3 DATA DEMONSTRATING EFFICACY AND SAFETY OF XEOMIN® (incobotulinumtoxinA) IN TREATING UPPER FACIAL LINES merzaesthetics.com ↗
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today topline results from two pivotal phase 3 clinical studies demonstrating the efficacy and safety of Xeomin® (incobotulinumtoxinA) in the simultaneous treatment of upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral canthal lines). |
| 2021-08-31 | Merz Pharmaceuticals GmbH | Regulatory XEOMIN® (incobotulinumtoxinA) Receives European Approval for the Treatment of Chronic Sialorrhea in Children merz.com ↗ |
| 2021-08-31 | Merz Therapeutics GmbH | Regulatory XEOMIN® (incobotulinumtoxinA) receives european approval for the treatment of chronic sialorrhea in children merztherapeutics.com ↗ |
| 2021-06-23 | Teijin America, Inc. | Regulatory Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A[Teijin Pharma] teijin.com ↗
Teijin Pharma has been granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity. |
| 2021-06-23 | Merz Pharmaceuticals GmbH | Regulatory Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A merz.com ↗
Teijin Pharma has been granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin ® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity. |
| 2021-06-23 | Merz Therapeutics GmbH | Regulatory Teijin receives additional approval in japan for Merz’s XEOMIN® Botulinum Toxin Type A merztherapeutics.com ↗
This label extension in Japan is another outstanding example for the benefits XEOMIN ® offers to many post-stroke spasticity patients. |
| 2020-07-09 | AbbVie | Regulatory FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity abbvie.com ↗ |
| 2020-07-01 | Merz Therapeutics GmbH | Regulatory Teijin receives marketing approval for Merz’s XEOMIN® Botulinum Toxin Type A in japan merztherapeutics.com ↗
Teijin Pharma has been granted approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market XEOMIN ® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity. |
| 2020-06-29 | Teijin America, Inc. | Regulatory Teijin Receives Marketing Approval for Merz’s Xeomin® Botulinum Toxin Type A in Japan[Teijin Pharma] teijin.com ↗
Teijin Pharma has been granted approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity. |
| 2020-06-29 | Merz Pharmaceuticals GmbH | Regulatory Teijin Receives Marketing Approval for Merz’s Xeomin® merz.com ↗
Teijin Pharma has been granted approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin ® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity. |
| 2019-04-08 | Evolus, Inc. | Results Evolus Announces Publication of Largest Aesthetic Head-to-Head Pivotal Trial Comparing Jeuveau™ and BOTOX® in Aesthetic Surgery Journal evolus.com ↗
Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 87.2% for Jeuveau™, 82.8% for BOTOX ® and 4.2% for Placebo at Day 30 |
| 2016-03-17 | Merz Pharmaceuticals GmbH | Regulatory Merz Announces European Approval of Bocouture for the Treatment of Upper Facial Lines merz.com ↗
Merz Pharma Group today announced that Bocouture ® has been approved by European regulatory authorities for the treatment of upper facial lines, including horizontal frown lines, lateral periorbital lines and glabellar frown lines. |
All press releases naming this drug 25 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Type A Botulinum toxin | “Patients will be treated with an injection of Type A Botulinum toxin.” NCT02325063 ↗ |
| Known as | BoNTA | “Botulinum toxin type A (BoNTA) has been reported to be effective for treatment of patients with neurogenic detrusor overactivity (NDO) refractory to anticholinergic agents.” PMID 20674149 ↗ Jul 2010 |
| Known as | Botulinum toxin type A | “Botulinum toxin type A (BoNTA) has been reported to be effective for treatment of patients with neurogenic detrusor overactivity (NDO) refractory to anticholinergic agents.” PMID 20674149 ↗ Jul 2010 |
| Known as | type A botulinic toxin | “Evaluation of the Efficacy and Tolerance of 2 Dosages of Type A Botulinic Toxin in Neurogenic Areactive Bladder Resistant to Oral Medical Treatment” NCT00213577 ↗ |
| Known as | Xeomin | “Patients randomized to this group will be treated with an injection of Type A Botulinum Toxin (Xeomin®, MERZ).” NCT02325063 ↗ |
| Route | Other | “intradetrusor injection” PMID 20674149 ↗ Jul 2010 |